Virus plus immunotherapy combo for advanced bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of an oncolytic virus plus lenvatinib and toripalimab (immunotherapy drugs) compared with the standard chemotherapy FOLFOX for advanced bile duct or gallbladder cancer. The goal is to see if the new combination helps people whose cancer has progressed after one line of treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have bile duct or gallbladder cancer that cannot be removed by surgery or has spread to other parts of the body.
- You have already tried one standard chemotherapy or other systemic treatment for this cancer, and it didn't work or caused too many side effects.
- You have at least one tumor that can be measured on a CT scan or MRI.
- You are generally well enough to be up and about (able to care for yourself, but may not be able to do heavy physical work).
- Your blood counts, liver, and kidney function are within acceptable limits, and you are expected to live at least 12 more weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
This study tests a combination of freezing the tumor (cryoablation), an investigational immunotherapy (QL1706), and a targeted therapy pill (lenvatinib) for people with advanced bile duct cancer that has progressed after initial treatment. The goal is to see if this new combination can help control the cancer and improve outcomes.
This study tests a combination of four drugs—two immunotherapy drugs (iparomlimab and toripalimab), a targeted therapy (bevacizumab), and chemotherapy—as a first-line treatment for advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to see if this combination can shrink tumors and help patients live longer.
This Phase 3 study tests whether toripalimab (an immunotherapy) combined with lenvatinib and chemotherapy works better than standard treatment for advanced intrahepatic cholangiocarcinoma. It aims to help people live longer and/or control the cancer more effectively.
This Phase 3 study tests whether a combination of lenvatinib, an immunotherapy medicine (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) works better for advanced bile duct cancer that cannot be fully removed by surgery. It may help people live longer or control the cancer for longer.
This trial tests a combination of three drugs for bile duct cancer that cannot be removed by surgery: sintilimab (an immunotherapy that helps your immune system fight cancer), bevacizumab (a drug that blocks blood vessel growth to tumors), and a standard chemotherapy called AG (gemcitabine and capecitabine). The goal is to see if this combination can help shrink or control the cancer as a first treatment option.
Hear when a new Biliary Tract Cancer (BTC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.